Recently, XAV939 has been shown to decrease neuroblastoma cell survival by inhibiting β-catenin transcriptional activity and decreasing expression of cyclin D1 in both MYCN-amplified and non-amplified cell lines [46]. Here, MYCN is linked to neuroblastoma.